Stephanie Mok

Modulari-T is a cell and gene therapy (CGT) company that has developed a second-generation In Vivo CGT Platform encompassing both novel receptors and novel vectors into the first truly in vivo system that can address numerous cell types, and significantly broaden the range of accessible solid tumor and autoimmune/inflammation targets. Our proprietary AI enabled protein design platform generates two distinct technology systems that combine to the first truly novel second-generation in vivo system: The MARC (Modular Actuation Receptor Complex): the genetic payload, designed to ensure long-term therapeutic response while minimizing toxic side effects - addressing key limitations of existing engineered cell therapies The MoVe (Modular Vector): customizable in vivo gene delivery vectors, enables specific in vivo delivery of MARCs to T and NK cells, simplifying manufacturing and reducing costs associated with cell therapies. The MARC and MoVe systems were built to enable each other but can be de-coupled and adapted to partner technology. Modulari-T is advancing a diverse pipeline of candidates covering a range of indications and modalities with significant data inflections expected in 2026. Our lead asset is slated to enter IND-enabling studies in 4Q2026 We are backed by top investors, including Box One, Y Combinator, Pioneer Fund and Hidden Layers. We will be seeking a $15M USD seed raise in 2026 to advance the lead asset into IND-enabling studies, and expand the company. In addition, we are seeking a range of business development partnerships that can exploit both the MARC and the MoVe platforms for novel target creation.